Brief: Inhibikase Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Ikt-001Pro
26/08/2022 14:09
Aug 26 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR IKT-001PRO FOR THE
TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
* INHIBIKASE THERAPEUTICS INC - LOOK FORWARD TO INITIATING A
BIOEQUIVALENCE STUDY FOR IKT-001PRO IN SECOND HALF OF 2022
Source text for Eikon: ID:nPnbXhLlJa
Further company coverage: IKT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary